Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Wojciech Jurczak(Jagiellonian University), Manish R. Patel(Sarah Cannon), Jonathon B. Cohen(Emory University), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Talha Munir(Leeds Teaching Hospitals NHS Trust), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Donald E. Tsai(University of Pennsylvania), Binoj C. Nair(Eli Lilly (United States)), Deepa Jagadeesh(Roswell Park Comprehensive Cancer Center), Constantine S. Tam(The Alfred Hospital), Krish Patel, James N. Gerson(UPMC Hillman Cancer Center), Toby A. Eyre(Oxford University Hospitals NHS Trust), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Paolo Abada(Eli Lilly (United States)), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Chan Y. Cheah(The University of Western Australia), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), John F. Seymour(The Royal Melbourne Hospital), Bita Fakhri(University of California, San Francisco), Minna Balbas(Roswell Park Comprehensive Cancer Center), Alvaro J. Alencar(University of Miami), Paolo Ghia(Vita-Salute San Raffaele University), Nirav N. Shah(Medical College of Wisconsin), William G. Wierda(University of Maryland, Baltimore), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Chunxiao Wang(Second Hospital of Shandong University), Ian W. Flinn(Tennessee Oncology), Amy S. Ruppert(The University of Texas MD Anderson Cancer Center), Denise Wang(Eli Lilly (United States))
Cited by 213
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k